The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer

Abstract

Background: Gastric cancer (GC) is the third leading fatal cancer in the world and its incidence ranked second among all malignant tumors in China. The molecular classification of GC, proposed by the The Cancer Genome Atlas (TCGA), was added to the updated edition (2019) of WHO classification for digestive system tumor. Although MSI and EBV subtypes appeared as ever-increasingly significant roles in immune checkpoint inhibitor therapy, the underlying mechanisms are still unclear. Methods: We systematically summarized the relationship between EBV, d-MMR/MSI-H subtypes and clinicopathological parameters in 271 GC cases. Furthermore, GSE62254/ACRG and TCGA-STAD datasets, originated from Gene Expression Omnibus (GEO) and TCGA respectively, were analyzed to figure out the prognosis related molecular characteristics by bioinformatics methods. Results: Patients with MSI subtype had better prognosis than the MSS subtype (P = 0.013) and considered as an independent biomarker by the univariate analysis (P = 0.017) and multivariate analysis (P = 0.050). While there was no significant difference between EBV positive and negative tissues (P = 0.533). The positive prognostic value conferred by MSI in different cohorts was revalidated via the clinical analysis of GSE62254/ACRG and TCGA-STAD datasets regardless of race. Then key gene module that tightly associated with better status and longer OS time for MSI cases was obtained from weighted gene co-expression network analysis(WGCNA). NUBP2 and ENDOG were screened from the gene cluster and oxidative phosphorylation, reactive oxygen species(ROS) and glutathione metabolism were analyzed to be the differential pathways in their highly expressed groups. Conclusions: Our results manifested the significant prognostic value of MSI in Chinese GC cohort and comparisons with other populations. More opportunities to induce apoptosis of cancer cells, led by the unbalance between antioxidant system and ROS accumulation, lay foundations for unveiling the better prognosis in MSI phenotype through the bioinformatics analysis.

Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

“…2 In addition, immune checkpoint therapy for advanced stage or metastatic EBVaGC may be effective in treating this disease. 30 Breast cancer. The first association of EBV infection with breast cancer was reported in 1995.…”

Identification of Key Genes Related to CD8+ T-Cell Infiltration as Prognostic Biomarkers for Lung Adenocarcinoma

“…Lung adenocarcinoma (LUAD) is the most common type of lung cancer, accounting for 40% of all lung cancers (1)(2)(3). In recent years, the development of immunotherapy has changed the landscape of non-small cell lung cancer (NSCLC) therapy (4)(5)(6). Notably, the immunotherapy effects mainly rely on the immune responses, which are significantly influenced by the tumor microenvironment (7,8).…”

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers

“…Presently, immune checkpoint inhibitors are commonly used for cancer therapy in several cancers, and ROS is closely associated with the tumor microenvironment and immunity [ 9 ]. ROS accumulation has been suggested to be associated with the anticancer effects of these compounds, including induction of cell death and prolongation of survival periods in gastric cancer and lung cancer [ 167 , 168 ]. There is an excellent review about the regulation of programmed-death ligand 1 (PD-L1) expression by ROS in cancer cells [ 169 ].…”